1 Near- and forecasting the SARS-COV-2 epidemic requires a global view and multiple methods
2 Daren Austin PhD ARCS DIC

- 3 Senior Fellow, Clinical Pharmacology Modelling & Simulation
- 4 GlaxoSmithKline Research and Development
- 5 Email: daren.j.austin@gsk.com
-
- 7 09/2020
7 09/2020

8 Abstract

j

45 and doubling time log(2)/r days. The SARS-COV-2 infection has an incubation of approximately 5

46 days and a typical time from case presentation to death of approximately 14-21 days^{4,5}. For any case

- 47 fatality rate (CFR) and duration, T, between presenting as a case and eventual death, the number of
- 48 deaths at a function of time is therefore $D(t) = CFR C(t T)$, which in the exponential phase is $D(t) =$ $\frac{4}{\sqrt{2}}$

74 74 unity. A DTR of greater than unity implies that deaths are outstripping cases (for any CFR),
75 suggesting intervention measures are necessary to prevent further unrestricted differential

76 exponential epidemic growth. An up-to-date analysis (Date 08/APR/2020) shows movement in UK

77 DTR (1.07, 95% CI 1.04, 1.10) relative to the Global average (1.05, 95% CI 1.03, 1.06), suggestive of

77 DER (1.07, 95% CI 1.07, 1.104, 1.104, 1.104, 1.104, 1.105, 95% CI 1.04, 95% CI 1.04, 1.05, 1.06, 1.06, 1.0
78 The effects of social distancing. 78 the effects of social distancing.

79 Near-casting using time-series projection

Forward projection time-series methods have been used for many years in multiple disciplines¹⁰.
81 Conventional time-series projections make assumptions regarding correlations in previous data to 82 inform on future observations. Propagation of uncertainty, however, often limits precision 83 (predictions are based on predictions not observations). The time-delay between cases and deaths

84 inherent in the SARS-COV-2 epidemic lends itself to an alternative novel time-series methodology

85 (Methods). Using past log-case data lagged to 7- and 14-days, and linear mixed-effects models we

86 predict future cases based on past observations, and further predict deaths using the same model.

87 All data is analysed in the log domain, with CFR described by a random effect to account for country-

88 to-country variability in reporting practices. The use of dual lag times incorporates a (weekly) rate of

89 change into the model. The minimum time delay of 7-days means that 7-day predictions are possible

90 based on past *observations* (14-day predictions require one observation and one prediction,

91 predictions beyond that use future predictions). This methodology opens a near-casting window on

91 predictions beyond that use future predictions, the methodology opens a near-casting window on
92 future events not available to conventional models, with the mixed-effects approach¹¹ allowing 92 — future events not available to conventional models, with the mixed-effects approach** allowing
93 — prediction in countries that are still early in their epidemic.

93 prediction in countries that are still early in their epidemic.

94 Figure 2 shows sample predictions for selected countries (cut-off date 08/APR/2020, rebased to 64
95 cases and 16 deaths, 50 countries included in the analysis dataset) of cumulative cases, deaths and 96 incidence. The model has a residual error of 11% (Extended Data) and is useful for near-casting of 97 the SARS-COV-2 epidemic in all countries included, with sufficient precision and sensitivity (to 7-14-98 day time delays in actions) for helpful decision-making. The strength of this approach is the

98 day time delays in actions) for helpful decision-making. The strength of this approach is the

99 population-method used. Information from the global epidemic informs on individual country
100 behaviour, and outlier behaviour can be identified early from individual country posterior model 99

-
- 101 behaviour can be identified early from individual countries of the individual country posterior model countries $\frac{1}{2}$ 101 parameters (not shown).

102 Long-term prediction using parametric epidemiological models
102 Eastern architecture parametric epidemiological models will be

120 Solution of the model for cumulative log(Cases) and log(Deaths) for country, i, with addition of 2018
121 population as a possible covariate in the model gives: 121 population as a possible covariate in the model gives:

 \overline{C} = (riverse \overline{C}) + \overline{C} = (riverse \overline{C})

141 In the ongoing SARS-COV-2 epidemic, multiple methods are available for projection of numbers of
142 cases and deaths. Without a means of projection, evaluation of the effectiveness (or otherwise) of 143 intervention methods will prove challenging. Traditional epidemiology models based on contact and 144 transmission patterns are important for planning intervention policies (e.g., mass vaccination and 145 treatment), but they may struggle with calibration in a new setting when key parameters for their 146 evaluation are poorly known. SARS-COV-2 presents such an example; an emergent global epidemic 147 where previous immunity is absent. Robust intervention decisions will, however, be insensitive to 147 where previous immunity is absent. Robust intervention decisions will, however, be insensitive to

173 173 direction. The advantage over traditional time-series approaches is that the first 7-days of
174 predictions are founded on past observations (not future predictions), thereby reducing 175 (exponential) error. Case fatality rate differences were well-described at the country level by a log-176 linear random effect. 177 For eventual long-term forecasting, a parametric epidemiological model is necessary. Without such a
178 model, a call on the location and size of the peak, and eventual size and duration of the epidemic, is

179 not possible. These parametric models suffer from uncertainties and parameter correlations that

180 make initial estimation and future very challenging from single country data. However, we find that

181 using global, rather than individual country, data, a non-linear mixed-effects Gompertz epidemio-

182 statistical model can describe the epidemic well with excellent parameter estimation and low

183 residual. Providing a prediction of the time course for any single country from the model, however,

184 requires some form of quality control. That quality control is provided by the near-casting model.

185 Once near-term prediction intervals for the two modelling approaches coalesce, it is possible to

186 move from near-casting to forecasting with confidence. Based on our most up-to-date analysis, this

187 coalescence has happened in Italy, and it is now possible to provide more confident forward

188 projections for that country and others. 188 projections for that country and others.

189 The power of the epidemio-statistical global mixed-effects analysis is that, like the two previous
190 approaches, countries further advanced in their epidemic inform on those following behind. We find 191 concordance between the two approaches in Italy, with support for an eventual epidemic size of 192 approximately 31.8k (95% CI 28.8k, 35.2k) deaths, with resolution by the beginning of July 2020. 193 Using the model, we also find support for a peak in the UK epidemic somewhere from 7/APR/2020 194 to 21/APR/2020, approximately 22.6k (95% CI 12.3, 26.5k) deaths, and resolution also by July 2020. 195 It is still too early to call the eventual global epidemic size, although values are predicted for every 196 country in the analysis dataset. All predictions are founded on a continuation of the current global 197 social distancing intervention program, which supports the use of a Gompertz epidemiological 197 social distancing intervention program, which supports the use of a Gomper

8

198 198 model. A relaxation of restrictions would release the brake on contacts, increase transmission,
199 invalidate future model assumptions, and most-likely lead to an extension of the epidemic duration.

-
- 200 Such predictions are out of scope for this analysis. 200 Such predictions are out of scope for this analysis.

201 Methods

- 202 Daily global data on new cases and deaths was downloaded from EDCD. Cumulative cases and
203 deaths were log-transformed for analysis. Data was selected based on number of rebased cases, and
-
- 204 time rebased from this point. Growth rate charts were calculated from geometric mean and
- 205 percentiles assuming log-normal distribution, with doubling time estimated by log-linear regression.
- 206 Doubling Time Ratio was estimated by separate log-linear random effects models, growth rates
- 207 merged, and 95% confidence intervals calculated. For time-series projection, log-cumulative cases
- 208 were lagged by 7- and 14-days prior to fitting a log-linear mixed-effects model with random
- 209 intercept and slopes. Log-cumulative deaths was fitted to predicted number of cases, also with
- 210 random intercept and slope. The epidemio-statistical Gompertz model was fitted to the same
- 211 analysis dataset. Predictions (mean and 95% CI) were back-transformed, differenced (for incidence
- 212 calculation) and overlaid with observation. Model goodness of fit was assessed visually and by Bayes
- 213 Information Criteria. All analyses were conducted in SAS 9.4 proc mixed and proc nlmixed.
- 214 automated by scripting and available from the author. At the time of publication, daily updated
- 215 global projections are ongoing. 215 global projections are ongoing.

216 References

- 217 1. World Health Organisation. (2019). Coronavirus disease (COVID-2019) situation reports.
218 Retrieved from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-
- 219 reports: <u>reports</u>
220 - 2. Li, Q., & Wu, P. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-
- 221 2. Li, C., & Wu, P. (2020). Early Transmission Dynamics in Wuhan, China, October Coronavirus-
221 Infected Pneumonia. **N Engl J Med**.. 382(13). 382(13). doi:doi:10.1056/NEJMoa2001316 221 Infected Pneumonia. N Engl J Med., 382(13), 382(13). doi:doi:10.1056/NEJMoa2001316

- 222 222 3. Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020). Substantial
223 undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). 3.
-
- 224 Science, eabb3221. doi: DOI: 10.1126/science.abb3221
- 225 4. Wang, D., Hu, B., & Hu, C. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019
- 226 1. Wang, D., Hu, B., E., B., B., B., Annes Patients of 138 Hospitalized Patients With 2019
226 Movel Coronavirus-Infected Pneumonia in Wuhan. China. JAMA. e201585.
- 226 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, e201585.
- doi:doi:10.1001/jama.2020.1585
228 5. Zhou, F., Yu, T., & Du, R. (2020). Clinical course and risk factors for mortality of adult inpatients
- 228 5. Zhou, F., Yu, T., & Du, R. (2020). Clinical course and risk factors for mortality of adult inpatients 229 with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395(10229), 1054–1002.
230 doi:doi:10.1016/S0140-6736(20)30566-3
-
- doi:doi:10.1016/S0140-6736(20)30566-3
231 6. Anderson, R. M., & May, R. M. (1992). Infectious Diseases of Humans: Dynamics and Control.
- 232 **6. Anderson, Control** Control, Control. Control. Anders and Publications.
- 233 7. Ferguson, N. M., Laydon, D., Nedjati-Gilani, G., & Imai, N. (2020). Impact of non-pharmaceutical
- 234 *interventions (NPIs) to reduce COVID19 mortality and healthcare demand. doi:DOI:*
- 235 https://doi.org/10.25561/77482
- 236 8. European Centre for Disease Prevention and Control. (2020). Publications and Data. Retrieved
- 237 from https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-
- 238 distribution-covid-19-cases-worldwide
- 239 9. Centers for Disease Prevention and Control. (2017). Clinical Growth Charts. Retrieved from
- 240 https://www.cdc.gov/growthcharts/clinical charts.htm
- 241 10. Montgomery, D. C., Jennings, C. L., & Kulahci, M. (2015). Introduction to Time Series Analysis
- 242 and Forecasting, 2nd Edition. Hoboken: Wiley-Interscience.
- 243 11. Demidenko, E. (1987). Mixed Models: Theory and Applications with R, Second Edition. New
- 244 York: Wiley Interscience. doi:10.1002/9781118651537 244 York: Wiley Interscience. Doi:1002/97811186515377911865153781186515378118651537811865153781186515378153781
1002/978118651537815378118651537811865153781186515378118651537811865153781186515378118651537811865153781186515
- 245 Acknowledgements

- 246 The author would like to acknowledge the European Centre for Disease Prevention and Control,
247 Without who's daily updated data, this work would not have been possible. This research is 246
-
- 248 dedicated to all who have lost their lives to this dreadful disease.

249 Competing Interests

-
- 250 The author is an employee and stockholder of GlaxoSmith Kline. This work was completed as part of
251 This ongoing employment duties. $\frac{3}{5}$ bis only duties.
- 252 Materials and Correspondence
- 253 Correspondence and requests for materials should be addressed to <u>daren.j.austin@gsk.com</u>.
254 Reprints and permissions information is available at www.nature.com/reprints.
- 254 Reprints and permissions information is available at www.nature.com/reprints.

255 Extended data

256 **Time-Series model**

- 257 Final parameters for linear mixed-effects Time-Series model of log(Cases); var1 = 7-day lagged
258 log(Cases), var2 = 14-day lagged log(Cases). GeoID = Country ID.
- log(Cases), var2 = 14-day lagged log(Cases). GeoID = Country ID.

260
261

261 Final parameters for linear mixed-effects Time-Series model of log(Deaths); var1 = 7-day lagged
262 $log \text{Ca}\text{se}\text{s}$), var2 = 14-day lagged log(Cases).

262 log(Cases), var $2 = 14$ -day lagged log(Cases).
263

266
267

267 **Gompertzian epidemio-statistical model** 268 Estimated model parameters and correlation matrix (population was excluded by BIC criteria)
269

271
272

272 Parameters are: r= growth rate, r/s = log-carrying capacity, a0 = initial condition, eps = residual, s2b1 =
273 variance(r), s2b2 = variance(a0), s2b3 = variance(logCFR), ALAG = lag time between cumulative 273 variance(r), s2b2 = variance(a0), s2b3 = variance(logCFR), ALAG = lag time between cumulative cases
274 and deaths, LNCFR = log(case fatality rate).

270 Figure 1

- 277 a) Growth curve for 2020 SARS-COV-2 global epidemic with UK data (not included in curve
278 estimation) overlaid rebased to 64 cases and 4 deaths. Geometric mean and 95% CI, median,
-
- 279 interquartile and interdecile ranges indicated. Data to 21/MAR/2020. b) Global exponential growth
- 280 rates for cumulative cases and deaths with UK indicated (21/MAR/2020, data rebased to 64 cases
- 281 and 4 deaths and fitted with a log-linear mixed effects model). c) Growth Rate Ratios for all
- 282 countries, values greater than unity indicate that the rate of growth of deaths is greater than cases
- 283 and may signify strains on healthcare (Data to 21/MAR/2020). 283 and may signify strains on healthcare (Data to 21/MAR/2020).
- 284 a)

Cumulative number of UK cases and deaths COVID-19 epidemic growth chart

Prediction based on time-matched non-UK data from 64 cases and 4 deaths. Geometric mean (95% CI), median P25/P75, P10/P90 Data from ECDC https://www.ecdc.europa.eu dated 2020-03-21

285

 $\frac{286}{3}$

287

288 288 c)

Log-linear mixed-effects analyses of data rebased to 64 cases and 4 deaths. Analysis is for 14 days from rebase Data from ECDC https://www.ecdc.europa.eu dated 2020-03-21

-
- 290 Figure 2
291 Near-term prediction of the ongoing UK SARS-COV-2 epidemic (mean and 95% prediction interval)
- 292 for the dual-lagged linear mixed effects model. Model shows cumulative cases and deaths and daily
- 293 case and mortality incidence. Near-casting (7-day) projection indicated. Data to 08/APR/2020. 293 case and mortality incidence. Near-casting (7-day) projection indicated. Data to 08/APR/2020.

Prediction based on global Time-Series model rebased to 64 cases and 16 deaths onw ards Geometric mean and 95% prediction interval shown. Data from ECDC https://www.ecdc.europa.eu dated 2020-04-08

Prediction based on global Time-Series model rebased to 64 cases and 16 deaths onw ards Geometric mean and 95% prediction interval shown. Data from ECDC https://www.ecdc.europa.eu.dated 2020-04-08

United_States_of_America

- Observation (Cases/day | Deaths/day | Cases | Deaths Prediction based on global Time-Series model rebased to 64 cases and 16 deaths onw ards Geometric mean and 95% prediction interval shown. Data from ECDC https://www.ecdc.europa.eu dated 2020-04-08

n
C

iulative Cas

es/Deaths

296 Figure 3

- 297 Posterior predicted course of the SARS-COV-2 epidemic for selected countries with near-term dual
- 298 lagged model predictions overlaid. Concordance in short-term predictions improves confidence in
- 299 the long-term projection Lack of concordance between prediction methods means that it is too early
- 300 to call the final size and shape of the UK epidemic.

Prediction based on global Epidemiological model rebased to 128 cases and 64 deaths onw ards Geometric mean and 95% prediction interval show n. Data from ECDC https://www.ecdc.europa.eu dated 2020-04-08

United_States_of_America

Prediction based on global Epidemiological model rebased to 128 cases and 64 deaths onw ards Geometric mean and 95% prediction interval shown. Data from ECDC https://www.ecdc.europa.eu dated 2020-04-08